Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (620)	1/29/2007 10:13:28 AM
From: tuck	Read Replies (1) \| Respond to of 802

>>Introgen's INGN 225 Molecular Cancer Vaccine Demonstrates Promising Results in Phase 2 Trial Monday January 29, 9:30 am ET AUSTIN, Texas--(BUSINESS WIRE)--Approximately half of patients with advanced small cell lung cancer responded to Introgen Therapeutics, Inc.'s (NASDAQ:INGN - News) INGN 225 molecular cancer vaccine in combination with subsequent chemotherapy. The encouraging Phase 2 clinical data were presented over the weekend by Introgen's collaborator Dr. Scott Antonia of the H. Lee Moffitt Cancer Center & Research Institute. Patients in the study achieved a 52 percent objective tumor response rate and 41 percent of patients were still alive one year after receiving the immunotherapy. Historically, tumor responses to second-line chemotherapy are between 6 and 30 percent and most patients survive for less than 6 months. The data imply that INGN 225 immunotherapy can sensitize cancer cells to the effects of chemotherapy restoring its effectiveness. INGN 225 is a cancer vaccine containing the p53 gene. p53 is called the "Guardian of the Genome," and is known to help restore normal cellular function and to promote apoptosis, or programmed cell death in abnormal cells such as cancer cells, allowing tumors to die when treated with chemotherapy. Dr. Antonia, associate professor in the Department of Interdisciplinary Oncology and Molecular Medicine, reported the data during the Fourth Biennial Meeting of Molecular Targets in Cancer Therapy in Clearwater Beach, Florida. An interim analysis of the phase 2 clinical trial was previously published in the medical journal Clinical Cancer Research. "Data from Introgen's study in lung cancer patients, as well as other published studies, supports the novel approach of using a combination of immunotherapy and chemotherapy to treat cancer patients," said Dr. Dmitry Gabrilovich, also of H. Lee Moffitt Cancer Center & Research Institute, organizer of the conference and co-principal investigator of the clinical trial. "INGN 225 sensitized tumors to the effects of platinum and taxane chemotherapies. Of particular interest, some patients who previously failed platinum chemotherapy responded to platinum re-treatment. These findings have important implications for improving the efficacy of these widely utilized cancer chemotherapies." INGN 225 is an immunotherapy (vaccine) that utilizes an adenovector to deliver the p53 gene to a patient's immune cells, stimulating an anti-tumor immune response. Induction of p53-specific immune responses were observed following INGN 225 therapy and were found to correlate with increased tumor responses to the administered chemotherapy.<< snip Cheers, Tuck